Galapagos CEO Henry Gosebruch says the recent uptick in M&A activity is a positive development for the biotech as it pursues ...

“This change is deeply troubling because it is false and lacks transparency. There is no scientific rationale for CDC to ...

Though CMC barriers remain, strategic planning in the early development stages can guide a CGT product to success, noted ...

Aspen Neuroscience has closed a Series C funding round, raising $115m for the clinical development of its cell therapy ...